Very good find , Hodgie ..announced by the FDA sometime Friday/ Saturday US time .
Just trying to evaluate "the sum of the parts " here , as regards where IMU are currently at .
As best I can recall :
1) IMU had 81 patients within a trial process ....Per Presentation July 2024
Immunotherapy platform expansion: azer-cel aLLO CD19 CAR T cell therapy Program2) FDA had granted FAST TRACK DESIGNATION for these trials ..per Announcement 19th March 2025 .
Am I correct in saying ( asking ) , that there has been "no further updates " on the Trials for these 81 patients since that Presentation ...and IF the next Phase2/3 , is what IMU now awaits from the FDA , DOES THIS FRIDAY FDA announcement puts this upgrade into a much higher likelihood ?
Apologies for asking , what others will likely be all over in this evaluation !
(20min delay)